PTAB invalidates Atossa's US Patent 11,572,334; new patent 12,201,591 issued

ATOSSA THERAPEUTICS, INC.

PTAB final decision found all claims of US Patent 11,572,334 unpatentable; Atossa will not appeal.
Atossa issued new US Patent 12,201,591 (Sustained Release Compositions of Endoxifen) with 31 claims.
Company states decision has no impact on current clinical formulations; will pursue continuation patent application.
Patent estate now includes four issued US patents covering formulations in development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.